MBRX vs. AADI, DRRX, HCWB, IMRX, ACXP, NRXP, EYEN, RVPH, LPCN, and VYNE
Should you be buying Moleculin Biotech stock or one of its competitors? The main competitors of Moleculin Biotech include Aadi Bioscience (AADI), DURECT (DRRX), HCW Biologics (HCWB), Immuneering (IMRX), Acurx Pharmaceuticals (ACXP), NRx Pharmaceuticals (NRXP), Eyenovia (EYEN), Reviva Pharmaceuticals (RVPH), Lipocine (LPCN), and VYNE Therapeutics (VYNE). These companies are all part of the "pharmaceutical preparations" industry.
Aadi Bioscience (NASDAQ:AADI) and Moleculin Biotech (NASDAQ:MBRX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, dividends, analyst recommendations, media sentiment, profitability, risk, institutional ownership, community ranking and valuation.
52.1% of Aadi Bioscience shares are owned by institutional investors. Comparatively, 15.5% of Moleculin Biotech shares are owned by institutional investors. 37.3% of Aadi Bioscience shares are owned by company insiders. Comparatively, 6.7% of Moleculin Biotech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Moleculin Biotech received 216 more outperform votes than Aadi Bioscience when rated by MarketBeat users. Likewise, 53.16% of users gave Moleculin Biotech an outperform vote while only 47.83% of users gave Aadi Bioscience an outperform vote.
Aadi Bioscience has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500. Comparatively, Moleculin Biotech has a beta of 1.85, indicating that its stock price is 85% more volatile than the S&P 500.
Moleculin Biotech has lower revenue, but higher earnings than Aadi Bioscience.
In the previous week, Aadi Bioscience had 3 more articles in the media than Moleculin Biotech. MarketBeat recorded 4 mentions for Aadi Bioscience and 1 mentions for Moleculin Biotech. Aadi Bioscience's average media sentiment score of 1.87 beat Moleculin Biotech's score of 0.53 indicating that Moleculin Biotech is being referred to more favorably in the news media.
Moleculin Biotech has a net margin of 0.00% compared to Moleculin Biotech's net margin of -288.72%. Moleculin Biotech's return on equity of -61.83% beat Aadi Bioscience's return on equity.
Aadi Bioscience currently has a consensus target price of $20.50, suggesting a potential upside of 1,038.89%. Moleculin Biotech has a consensus target price of $35.00, suggesting a potential upside of 633.75%. Given Moleculin Biotech's higher probable upside, research analysts clearly believe Aadi Bioscience is more favorable than Moleculin Biotech.
Summary
Moleculin Biotech beats Aadi Bioscience on 8 of the 15 factors compared between the two stocks.
Get Moleculin Biotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for MBRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MBRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Moleculin Biotech Competitors List
Related Companies and Tools
